

Jennifer R. Klemp, MPH, MA

**Breast Cancer Prevention Center
University of Kansas Hospital
3901 Rainbow Blvd., Room 1347 Bell
Kansas City, KS 66160
Phone: (913) 588-3662
Fax: (913) 588-3679
Pager: (913) 917-8262
e-mail: jklemp@kumc.edu**

Education and Training

- Ph.D. Candidate** **University of Kansas, Lawrence, KS (Anticipated 2006)**
Clinical Psychology (Health Specialty)
Dissertation: Evaluating the Effects of Adjuvant Chemotherapy given Q2W or Q3W on Serum Neurobiomarkers, Quality of Life and Cognition in Pre-menopausal Women with Invasive Breast Cancer: Pilot Study
- M.A.** **University of Kansas, Lawrence, KS, May 2003**
Master of Arts: Clinical Psychology
Thesis: Does Genetic Testing Affect Preventive Health Behaviors in Women at High Risk for Developing Breast Cancer? Patients' Perspectives.
Advisors: Carol J. Fabian, M.D. & Annette Stanton, Ph.D.
- M.P.H.** **University of Kansas School of Medicine, Kansas City, KS, May 1999**
Masters in Public Health
Thesis: Future Mammography Screening Compliance in Underserved Urban Women after a Mobile Mammography and Educational Intervention
Advisors: Carol J. Fabian, M.D. & Edward Ellerbeck, M.D., MPH
*Graduate coursework in public health including epidemiology and statistics.
*Received the W.S. Sutton Scholarship in Genetic Research
- Johns Hopkins University, Baltimore, MD, 1998**
Summer Program in Public Health
*Graduate coursework in epidemiology, genetic epidemiology, cancer epidemiology, and health care systems
- University of Michigan- Ann Arbor, MI, 1997**
Summer Program in Epidemiology
*Graduate coursework in cancer prevention and statistical outcomes
- University of Missouri-Kansas City- Kansas City, MO, 1995-96**
M.S. program in Molecular Biology and Biochemistry
*Graduate course work in biochemistry, microbiology, and immunology.
- B.A.** **University of Kansas- Lawrence, KS, 1994**
Biology (Concentration in genetics)

Professional Education:

Klemp, JR

Fox Chase Cancer Center-Philadelphia, PA, 2000

Advanced Course in Cancer Genetic Risk Counseling

*Course to strengthen counseling skills and to focus on: ethical, legal, and social issues related to genetic information. Focus on medical management of high risk individuals and current and new testing methodologies

Fox Chase Cancer Center- Philadelphia, PA. 1996

Familial Cancer Risk Counseling

*Participated in a clinical course on risk counseling for breast, ovarian, and colon cancers.

Professional and Clinical Experience:

1996-

Present

University of Kansas Medical- Kansas City, KS

Research Instructor and Cancer Risk Counselor

Clinical Research Trials Coordinator

High Risk and Prevention Breast Program Coordinator

*Promoted to Research Faculty in the Department of Medicine, Division of Clinical Oncology: July 2001

*Function as a cancer risk counselor providing: 1) a comprehensive assessment (including the use of validated risk models) of cancer risk factors, 2) identify individuals and their families at increased risk for cancer, 3) provide education regarding cancer genetics and hereditary cancer syndromes, 4) offer preventive strategies including: screening options and frequency, clinical trials, diet, exercise, chemoprevention, prophylactic surgery, 5) perform genetic counseling and provide access to testing through clinical or research protocols, 6) provide necessary follow-up and support for individuals and their families post genetic testing.

*PI of a study looking at the use of a cognitive protectant to help maintain quality of life and cognition in premenopausal women with breast cancer receiving adjuvant chemotherapy.

*Previously managed activities for participants in the High Risk & Prevention Breast Cancer Program including risk counseling, breast health education, and breast tissue biomarker evaluation. Work under the direction of Carol Fabian, M.D., Medical Director of the Breast Cancer Prevention Center.

*Assisted in the Organization of a National Cancer Institute Grant Titled *A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (SERM-3) in High Risk Women with Fine Needle Aspiration Cytologic Evidence of Hyperplasia*. This program includes genetic testing of women at high risk for breast cancer and a cross-over clinical trial administering a chemoprevention agent (200 participants).

*Coordinated or assisted with clinical research trials funded through the NCI and regional funding sources. Including 3 NCI funded grants and contracts and 3 regionally funded grants in the areas of breast chemoprevention and experimental screening techniques.

*Aid in the writing of grants, abstracts, and publications based on research projects; breast and colon cancer prevention. Independently wrote and was awarded a grant funded by the Kansas Department of Health & Environment through the Kansas Breast & Cervical Cancer Initiative.

*Coordinated the Susan G. Komen Foundation Mobile Mammography Program-offering no cost mammography to women who qualify co-sponsored by church and civic organizations. Grant funded by the Kansas City Susan G. Komen Foundation (awarded 1996-2000).

- 2003- Present** **University of Kansas, Lawrence, KS.**
Clinical Psychology Trainee (Health Specialty)
 Provide therapy and assessments in both a University Psychological Clinic and an Academic Medical Center. Specific work includes CBT, solution focused therapy, and cancer prevention and healthy lifestyle modification. Specific assessment work includes evaluation of cognition in oncology patients using the High Sensitive Cognitive Screen and measures to assess quality of life specific to work in premenopausal women with breast cancer.
- Instructor- Fall 2003**
 Health Psychology (Undergraduate and Graduate Level course)
- 8/2000-10/2001** **University of California – San Francisco Medical Center**
(Consultant) **Clinical Coordinator: Breast Cancer Prevention Program**
Carol Franc Buck Breast Care Center: Laura Esserman, MD, Director
 *Developed a clinic framework for the Breast Cancer Prevention Program
 *Implemented the clinical framework into a multi-disciplinary breast clinic
 *Manage clinical and research aspects of the prevention program
 *Grant writing, clinical trials and protocol development, design community based outreach and screening programs
- 1995-1996** **University of Missouri-Kansas City- Kansas City, MO**
Graduate Student and Graduate Teaching Assistant
 *Graduate student: Master's Program in Molecular Biology and Biochemistry
 *Graduate teaching assistant: taught Microbiology and Anatomy Laboratories
- 1994-1995** **USD #453, Leavenworth High School- Leavenworth, KS**
Substitute teacher
 *Taught secondary school biology, chemistry, and physics as a long-term substitute (while serving as my mother's primary care-giver during her battle with breast cancer including chemotherapy, bone marrow transplantation, and radiation therapy).
- 1991-1993** **University of Kansas Medical Center- Kansas City, KS**
Genetics and Endocrinology Intern
 *Attended weekly genetic counseling clinics (under the mentorship of R. Neil Schimke, M.D.) specializing in adult onset of genetically inherited diseases.
 *Aided in the organization of a Human Genome Project Workshop for secondary school teachers held annually in Kansas City- funded by a grant from the Department of Energy

Grant Awards:

The use of a cognitive protectant to help maintain quality of life and cognition in premenopausal women with breast cancer receiving adjuvant chemotherapy. Department of Defense Breast Cancer Research Program Pre-Doctoral Fellowship Award. (PI) 2003-2006.

Erythropoiesis Stimulating Protein (darbepoetin alfa) as a Quality of Life Enhancer and Cognitive Protectant in Women with Invasive Breast Cancer Receiving Four Cycles of Adjuvant Chemotherapy: Randomized Pilot Study (PI): Amgen Pharmaceuticals. 2002-2005.

Phase II Chemoprevention Trial of Soy vs. Tamoxifen for Breast Cancer Prevention in High Risk Pre-Menopausal Women: Protocol Development and Program Coordinator. Department of Defense Breast Cancer Research Program (UCSF) 2001-2003.

A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381 •HCl, SERM-3) in High Risk Women with Fine Needle Aspiration Cytologic Evidence of Hyperplasia: Cancer and Genetic Risk Counselor/Research Coordinator. NCI funded trial initiated: Fall 1998, KUMC.

A Phase II Clinical Trial of the Chemopreventive Agent DiFluoroMethylOrnithine (DFMO) in Breast Dysplasia with Biomarker Abnormalities: Cancer and Genetic Risk Counselor/Research Coordinator. NCI funded trial initiated: Spring 1997. Completed Accrual: Spring 1999, KUMC.

Susan G. Komen Foundations Mobile Mammography and Risk Assessment Program. Program Manager and Risk Counselor. 1996-2000. KUMC.

Kansas Breast and Cervical Cancer Initiative: Breast Health Outreach and Education Program. Program Manager and Risk Counselor (Co-PI). Funded 1997, KUMC.

Publications:

Klemp JR, Miller M, Richter K, Stanton AL, Chamberlain C, Fabian CJ. Women at high risk for breast cancer seek complements to careful surveillance. Planned submission: August 2004.

Ozane E, **Klemp JR**, Esserman L. A Decision Framework for Breast Cancer Prevention. Submitted to *JNCI* July 2004.

Klemp JR, O'Dea A, Chamberlain C, Fabian CJ. Patient Satisfaction of BRCA 1/2 Genetic Testing by Women at High Risk for Breast Cancer Participating in a Prevention Trial. Submitted to *Familial Cancer*: April 2004

Klemp JR, Terranova P, Hamidpour S, Hall M, Elia M, Fabian CJ. Variation of nipple aspirate fluid concentrations of estrone and estradiol in mammary ducts and serum in high-risk women. Submitted to *Cancer Epidemiology, Biomarker, and Prevention*: Conditionally accepted April 2004.

Sharma P, **Klemp JR**, Simonsen M, Welsko CM, Zalles CA, Kimler BF, Fabian CJ. Failure of High Risk Women to Produce Nipple Aspirate Fluid Does Not Exclude Detection of Cytologic Atypia in Random Periareolar Fine Needle Aspiration Specimens. Accepted to *Breast Cancer Research and Treatment*: March 2004.

Euhus DM, Smith KC, Robinson L, Stukey A, Olapade F, Cummings S, Garber J, Chittendon A, Mills GB, Rieger P, Crawford B, Hughes KS, Roche C, Gantz P, Seldon J, Fabian CJ, **Klemp JR**, Tomlinson G. Pre-test Prediction of BRCA1 or BRCA2 Mutation by Risk Counselor and the Computer Model BRCAPRO. *JNCI* 2002; 94 (11):844-851.

Klemp JR and Fabian CJ. Usage and Patient Satisfaction of BRCA1/2 Genetic Testing by High Risk Women. Manuscript submitted to *Journal of Medical Genetics*, March 2002.

Fabian CJ, Kimler BF, Zalles CM, **Klemp JR**, Mayo M. Short-term Development of Breast Cancer is Predicted by Fine Needle Aspiration. *JNCI* 2000;92(15):1217-1227.

Klemp JR, Brady D, Frank TS, Kimler BF, Fabian CJ. Incidence of BRCA1/2 Mutation Carriers in a High Risk Cohort Participating in a Phase II (Biomarker) Chemoprevention Trial. *European J Cancer* 2000; 36:1209-1214.

Beisecker, AE., Selenke, D., Brecheisen, M., **Klemp, J.**, Simon, C., Fabian, CJ., Reaction to biomarker information of women at high risk for breast cancer. *Proc Am Prev Oncol*, 1997.

Klemp JR, Simon C, Ellerbeck E, Mayo M, Ahluwalia JS, Fabian CJ. Future Mammography Screening Compliance in Underserved Urban Women After a Mobile Mammography and Educational Intervention. Manuscript written for submission.

Brecheisen M, Selenke D, **Klemp JR**, Beisecker A, Fabian C. The Relationship of Perceived Risk, Coping Style, and Distress in Women at High Risk for Breast Cancer. Paper submitted to *Psycho-Oncology*.

Abstracts and Posters:

Klemp JR, Miller M, Richter K, Stanton AL, Chamberlain C, Fabian CJ. Women at High Risk for Breast Cancer Seek Complements to Careful Surveillance. Submitted: American Society of Clinical Oncology. May 2003, Chicago, IL.

Zalles C, Masood S, Clark J, Simonsen M, **Klemp JR**, Fabian CJ. Comparative Cytomorphology of Ductal Epithelial Cells Obtained by Ductal Lavage (DL) and Random Periareolar Fine Needle Aspiration (RPFNA) in Women at High Risk for Breast Cancer. Presentation: American Association for Cancer Research, April 5-9, 2003, Toronto, Canada.

Fabian CJ, **Klemp JR**, Terranova PT. Naf estrogen levels in high risk women: importance of microenvironment and rationale for use of aromatase inhibitors for chemoprevention in women receiving hormone replacement therapy. Susan Love Symposium "Intraductal Approach to Breast Cancer", March 27-30, Santa Barbara, CA.

Klemp JR, Terranova P, Hamidpour S, Elia M, Fabian CJ. Substantial variation of NAF estrone and estradiol levels between ducts in high-risk women. San Antonio Breast Cancer Symposium December 11-14, 2002. San Antonio, TX.

Fabian CJ, **Klemp JR**, Simonsen M, Welsko C, Zalles C. Comparison of Random Periareolar FNA Cytology Patterns in High-Risk NAF Producers versus Non-NAF Producers. San Antonio Breast Cancer Symposium December 11-14, 2002. San Antonio, TX.

Zalles, CM, Simonson, M, **Klemp, JR**, Clark, J, Kimler, BF, Fabian, CJ. Cytomorphology and Epithelial Cell Yields in Specimens Obtained by Random Periareolar Fine Needle Aspiration and Ductal Lavage of the Breast in High Risk Women. American Society of Cytopathology 50th Annual Scientific Meeting, November 5-9, 2002, Salt Lake City, UT.

Elia M, Handipour S, Terranova P, Anderson J, **Klemp JR**, Fabian CJ. Marked variation in the nipple aspirate fluid (NAF) estrogen concentration and NAF/serum ratios between ducts in high-risk women. Accepted abstract to the American Association of Cancer Research, 93rd Annual Meeting, San Francisco, CA, April 6-10, 2002.

Euhus DM, Smith KC, Robinson L, Stuke A, Olapade F, Cummings S, Garber J, Chittendon A, Mills GB, Rieger P, Crawford B, Hughes KS, Roche C, Gantz P, Sheldon J, Fabian CJ, **Klemp JR**, Tomlinson G. BRCAPRO Enhances the Performance of Risk Counselors for Differentiating BRCA Gene Mutation Carriers from Non-Carriers Based on Nuclear Pedigree Information. Accepted abstract to the 2001 Annual Meeting of the American Society of Clinical Oncology (ASCO), San Francisco, CA, May 2001.

Ozanne E, Howard R, **Klemp JR**, Rockhill B, Esserman L. Risk assessment guidelines for breast cancer prevention used in a shared medical decision making setting. Abstract accepted. 23rd Annual Meeting of the Society for Medical Decision Making October 2001, San Diego, CA.

Klemp JR, Fabian CJ. Initial Phone disclosure of BRCA1/2 results is acceptable in high risk women. Abstract accepted and poster presented: American Society of Human Genetics. Annual meeting: October 2000, Philadelphia, PA.

Klemp JR, Fabian CJ, Brady D. Incidence and Therapeutic Options of BRCA1/2 Carriers: High Risk Cohort Participating in a Phase II Chemoprevention Trial. Accepted Poster Presentation: 36th American Society of Clinical Oncology Annual Meeting. May 20-23, New Orleans, Louisiana.

Klemp JR, Brady D, Kimler BF, Manley S, Frank TS, Fabian CJ. Sensitivity of Combined Allele Specific Oligonucleotide Testing for common Mutation Plus Protein Truncation Assay vs. Full Gene Sequencing for Detection of BRCA1 and BRCA2 Mutations. Poster Presentation: 24th Annual Meeting of the American Society of Preventive Oncology (ASPO), March 5-7, 2000, in Bethesda, MD.

Miller-Schlyer M, Richter K, **Klemp JR**, Mayo M, Ahluwalia J, Fabian C. Does BRCA1/2 Testing Affect Preventive Health Behaviors? Patients' Perspective. Poster Presentation: The Second National Conference on Genetics and Disease Prevention, Baltimore, MD. December, 1999

Klemp JR, Ellerbeck E, Mayo M, Fabian C. Future Screening Compliance in Underserved Urban Women After a Mobile Mammography and Educational Intervention. Poster Presentation: American Society of Preventive Oncology, Houston, TX, March 1999.

Klemp JR, Fabian CJ, Johnson C, Simon C, Barnes J, Chang J. "Future Mammography Compliance by Underserved Urban Women after a Mobile Mammography and Educational Intervention". Poster Presentation: American Society of Preventive Oncology, March, 1998.

Klemp JR, Fabian CJ, Simon C, Barnes J, Chang J. "Future mammography compliance by underserved urban woman after mobile mammography and educational intervention". Poster Presentation: Kansas Public Health Association Annual Meeting, Hutchinson, Kansas, October 13-14, 1997.

Presentations/Lectures/Interviews:

Klemp JR. Preventing Breast Cancer. Kansas Public Radio and National Public Radio. May 17, 2004. <http://www.health.kansaspublicradio.org/>

Klemp JR. Survivor Quality of Life & Cognition. KUMC Breast Cancer Support Group, Kansas City, KS. September 12, 2002.

Klemp JR. Televison Interview: Importance of Family History. July 22,2002. KSHB Channel 41.

Klemp JR. Cancer Risk Assessment and Patient Management. 23rd Annual Ob-Gyn Update. The Femal Patient: Controversies in Obstetrics and Gynecology. June 14, 2002. Wichita, KS.

Klemp JR. Cancer Prevention. 55th International Institute of Municipal Clerks Annual Conference. Kansas City, MO. May 22, 2001.

Klemp, JR: Incorporating Prevention into Clinical Care. The Postgraduate Course in General Surgery- Current Cancer Management, San Francisco, CA., April 6, 2001.

Smith KC, Tomlinson G, Robinson L, Stukey A, Olapade F, Cummings S, Garber J, Chittendon A, Mills GB, Rieger P, Crawford B, Hughes KS, Roche C, Gantz P, Sheldon J, Fabian CJ, **Klemp JR**, Euhus DM. Accuracy of Risk Counselors and a Computer Model (BRCA^{PRO}) for Identifying Women Likely to Carry BRCA Gene Mutations. Presented: 19th Annual Meeting of the National Society of Genetic Counselors, Nov. 1-5, 2000, Savannah, GA.

Klemp JR. “Women at High Risk for Breast Cancer: Options for Surveillance and Prevention”. Lecture presented: American Society of Peri-Anesthesia Nurses 19th National Conference, April 19, 2000.

Klemp JR, Brady D, Frank TS, Kimler BF, Fabian CJ. Incidence of BRCA1/2 Mutation Carriers in a High Risk Cohort Participating in a Phase II (Biomarker) Chemoprevention Trial. Oral Presentation: Tumor Prevention and Genetics 2000: 1st International Conference and 5th Annual Conference of the International Society of Cancer Chemoprevention. Feb 17-19, 2000, St. Gallen, Switzerland.

Klemp JR. Future Mammography Screening Compliance in Underserved Urban Women After a Mobile Mammography and Educational Intervention. Thesis, date defended: April 6, 1999.

Klemp JR. Techniques for Managing Women at High Risk for Breast Cancer: Genetic Testing and Fine Needle Aspiration. Lecture presented: New Investigators Workshop, American Society of Preventive Oncology, Houston, TX, March 1999.

Klemp JR. Presented: Chemoprevention and Estrogen Replacement Therapy. Breast Cancer Symposium. Kansas Breast & Cervical Cancer Initiative. May 1998, Salina, KS.

Klemp JR. Presented: “Why are risk factors risky” at the Kansas Breast & Cervical Cancer Coalition’s Partners Meeting for the “Free to Know” Educational Program. May 1997, Topeka, KS.

Current Professional Organizations and Activities:

American Association of Cancer Research: Associate Member & Women in Cancer Member

American Society of Clinical Oncology: Affiliate Member

Kansas Masonic Cancer Research Institute Member: Breast and Ovarian Cancer Program

Facing our Risk Empowered (FORCE): Advisory Board

University of Kansas School of Medicine Women in Medicine & Science: Member